Clinical trial
A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors
NCT07915856 is registered in ClinicalTrials.gov with Shanghai Qilu Pharmaceutical Research and Development Center LTD as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started January 2027. Interventional study, Phase 1, 70 participants (estimated). Lead sponsor Shanghai Qilu Pharmaceutical Research and Development Center LTD. Primary measures: Safety and Tolerability: Incidence and Severity of Adverse Events; Incidence of Dose-Limiting Toxicities (DLTs) and 2 more.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors
- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of QLS5314 Monotherapy in Participants With Advanced Solid Tumors
- Lead sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- January 26, 2027
- Completion date
- October 26, 2029
- Enrollment
- 70 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them.
advanced solid tumors
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| QLS5314 Monotherapy | Experimental | QLS5314 |
Primary endpoints
Registered primary outcome measures; 4 primary.
| Measure | Time frame |
|---|---|
| Safety and Tolerability: Incidence and Severity of Adverse Events | From informed consent through 30 days (±7 days) after the last dose; treatment for up to 2 years. |
Show registry wordingNumber and percentage of participants with adverse events (AEs), treatment-emergent AEs (TEAEs), treatment-related AEs (TRAEs) and serious AEs (SAEs), by severity graded according to NCI-CTCAE v6.0 and relationship to QLS5314. | |
| Incidence of Dose-Limiting Toxicities (DLTs) | Cycle 1 Days 1-21 following first administration of QLS5314. |
Show registry wordingNumber and percentage of participants with protocol-defined DLTs during the Phase 1a dose-escalation stage. | |
| Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) | From the first dose until completion of Phase Ia dose escalation, up to approximately 11 months. |
Show registry wordingMTD established using protocol-defined dose-escalation rules, or MAD if an MTD is not established. | |
| Recommended Phase 2 Dose (RP2D) | From the first dose until determination of the RP2D, up to approximately 20 months. |
Show registry wordingRP2D determined using cumulative safety, tolerability, pharmacokinetic, immunogenicity, pharmacodynamic, biomarker and preliminary efficacy data. | |
Lead sponsor's other trials
Shanghai Qilu Pharmaceutical Research and Development Center LTD, most recent start first.
+1 more trial